Among them, tagraxofusp (SL-401), a CD123-targeting fusion protein conjugated to diphtheria toxin, has been FDA-approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is being evaluated in AML [84]. The gene discussed is IL3RA; the disease is CD4+/CD56+ hematodermic neoplasm.